|
|
Volumn 62, Issue 6, 2015, Pages 1439-1440
|
|
Is it worthy of switching to PegIFN alfa-2a in patients achieving virological suppression with entecavir?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADEFOVIR;
ALANINE AMINOTRANSFERASE;
ENTECAVIR;
HEPATITIS B SURFACE ANTIGEN;
HEPATITIS B(E) ANTIGEN;
PEGINTERFERON ALPHA2A;
ALPHA INTERFERON;
GUANINE;
MACROGOL DERIVATIVE;
ALANINE AMINOTRANSFERASE BLOOD LEVEL;
DNA REPLICATION;
DRUG EFFICACY;
DRUG SAFETY;
DRUG SUBSTITUTION;
DRUG WITHDRAWAL;
HEALTH CARE COST;
HEPATITIS B;
HISTOLOGY;
HUMAN;
LETTER;
LIVER CELL CARCINOMA;
LIVER FAILURE;
LONG TERM CARE;
PRIORITY JOURNAL;
PROTEIN BLOOD LEVEL;
RISK REDUCTION;
SEROCONVERSION;
TREATMENT DURATION;
TREATMENT OUTCOME;
VIRUS RESISTANCE;
ANALOGS AND DERIVATIVES;
BLOOD;
FEMALE;
HEPATITIS B VIRUS;
MALE;
FEMALE;
GUANINE;
HEPATITIS B E ANTIGENS;
HEPATITIS B SURFACE ANTIGENS;
HEPATITIS B VIRUS;
HEPATITIS B, CHRONIC;
HUMANS;
INTERFERON-ALPHA;
MALE;
POLYETHYLENE GLYCOLS;
|
|
EID: 84929605947
PISSN: 01688278
EISSN: 16000641
Source Type: Journal
DOI: 10.1016/j.jhep.2015.01.041 Document Type: Letter |
|
Times cited : (2)
|
|
References (5)
|
